Request for Nominations for Voting Members on the Tobacco Products Scientific Advisory Committee, 55574-55575 [2019-22685]
Download as PDF
55574
Federal Register / Vol. 84, No. 201 / Thursday, October 17, 2019 / Notices
Dated: September 25, 2019.
Reid P. Harvey,
Director, Clean Air Markets Division, Office
of Atmospheric Programs, Office of Air and
Radiation.
ENVIRONMENTAL PROTECTION
AGENCY
[FRL–10001–22–OAR]
Acid Rain Program: Excess Emissions
Penalty Inflation Adjustments
Environmental Protection
Agency (EPA).
[FR Doc. 2019–22696 Filed 10–16–19; 8:45 am]
BILLING CODE 6560–50–P
AGENCY:
ACTION:
FEDERAL DEPOSIT INSURANCE
CORPORATION
Notice of annual adjustment
factors.
Sunshine Act Meetings
The Acid Rain Program
requires sources that do not meet their
annual Acid Rain emissions limitations
for sulfur dioxide (SO2) or nitrogen
oxides (NOX) to pay inflation-adjusted
excess emissions penalties. This
document provides notice of the annual
adjustment factors used to calculate
excess emissions penalties for
compliance years 2019 and 2020.
TIME AND DATE:
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Jason Kuhns at (202) 564–3236 or
kuhns.jason@epa.gov.
The Acid
Rain Program limits SO2 and NOX
emissions from fossil fuel-fired
electricity generating units. All affected
sources must hold allowances sufficient
to cover their annual SO2 mass
emissions, and certain coal-fired units
must meet annual average NOX
emission rate limits. Under 40 CFR 77.6,
any source that does not meet these
requirements must pay an excess
emissions penalty without demand to
the EPA Administrator. The automatic
penalty is computed as the number of
excess tons of SO2 or NOX emitted times
a per-ton penalty amount of $2,000
times an annual adjustment factor,
which must be published in the Federal
Register.
The annual adjustment factor used to
compute excess emissions penalties for
compliance year 2019 is 2.0236,
resulting in an automatic penalty
amount of $4,047 per excess ton of SO2
or NOX emitted in 2019. In accordance
with 40 CFR 77.6(b) and 72.2, this
annual adjustment factor is determined
from values of the Consumer Price
Index for All Urban Consumers (CPI–U)
for August 1989 and August 2018.
The annual adjustment factor used to
compute excess emissions penalties for
compliance year 2020 is 2.0591,
resulting in an automatic penalty
amount of $4,118 per excess ton of SO2
or NOX emitted in 2020. This annual
adjustment factor is determined from
values of the CPI–U for August 1989 and
August 2019.
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:26 Oct 16, 2019
Jkt 250001
Pursuant to the
provisions of the ‘‘Government in the
Sunshine Act’’ (5 U.S.C. 552b), notice is
hereby given that at 10:43 p.m. on
Tuesday, October 15, 2019, the Board of
Directors of the Federal Deposit
Insurance Corporation met in closed
session to consider matters related to
the Corporation’s supervision,
corporate, and resolution activities.
PLACE: The meeting was held in the
Board Room located on the sixth floor
of the FDIC Building located at 550 17th
Street NW, Washington, DC.
STATUS: The meeting was closed to the
public.
MATTERS TO BE CONSIDERED: In calling
the meeting, the Board determined, on
motion of Director Martin J. Gruenberg,
seconded by Kathleen L. Kraninger
(Director, Consumer Financial
Protection Bureau), and concurred in by
Director Joseph M. Otting (Comptroller
of the Currency) and Chairman Jelena
McWilliams, that Corporation business
required its consideration of the matters
which were to be the subject of this
meeting on less than seven days’ notice
to the public; that no earlier notice of
the meeting was practicable; that the
public interest did not require
consideration of the matters in a
meeting open to public observation; and
that the matters could be considered in
a closed meeting by authority of
subsections (c)(4), (c)(6), (c)(8),
(c)(9)(A)(ii), and (c)(9)(B) of the
‘‘Government in the Sunshine Act’’ (5
U.S.C. 552b(c)(4), (c)(6), (c)(8),
(c)(9)(A)(ii), and (c)(9)(B).
CONTACT PERSON FOR MORE INFORMATION:
Requests for further information
concerning the meeting may be directed
to Robert E. Feldman, Executive
Secretary of the Corporation, at 202–
898–7043.
Dated at Washington, DC, on October 15,
2019.
Federal Deposit Insurance Corporation.
Robert E. Feldman,
Executive Secretary.
[FR Doc. 2019–22775 Filed 10–15–19; 4:15 pm]
BILLING CODE 6714–01–P
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
FEDERAL ELECTION COMMISSION
Sunshine Act Meetings
Tuesday, October 22,
2019 at 10:00 a.m.
PLACE: 1050 First Street NE,
Washington, DC.
STATUS: This meeting will be closed to
the public.
MATTERS TO BE CONSIDERED: Matters
concerning participation in civil actions
or proceedings or arbitration.
CONTACT PERSON FOR MORE INFORMATION:
Judith Ingram, Press Officer, Telephone:
(202) 694–1220.
TIME AND DATE:
Vicktoria J. Allen,
Acting Deputy Secretary of the Commission.
[FR Doc. 2019–22811 Filed 10–15–19; 4:15 pm]
BILLING CODE 6715–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–3263]
Request for Nominations for Voting
Members on the Tobacco Products
Scientific Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is requesting
nominations for members to serve on
the Tobacco Products Scientific
Advisory Committee, in the Center for
Tobacco Products. FDA seeks to include
the views of women and men, members
of all racial and ethnic groups, and
individuals with and without
disabilities on its advisory committees
and, therefore, encourages nominations
of appropriately qualified candidates
from these groups.
DATES: Nominations received on or
before December 16, 2019 will be given
first consideration for membership on
the Tobacco Products Scientific
Advisory Committee. Nominations
received after December 16, 2019 will be
considered for nomination to the
committee as later vacancies occur.
ADDRESSES: All nominations for
membership should be sent
electronically by logging into the FDA
Advisory Nomination Portal: https://
www.accessdata.fda.gov/scripts/
FACTRSPortal/FACTRS/index.cfm, or
by mail to Advisory Committee
Oversight and Management Staff, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 5103,
Silver Spring, MD 20993–0002.
SUMMARY:
E:\FR\FM\17OCN1.SGM
17OCN1
Federal Register / Vol. 84, No. 201 / Thursday, October 17, 2019 / Notices
FOR FURTHER INFORMATION CONTACT:
Regarding all nomination questions for
membership, the primary contact is:
Janice O’Connor, Office of Science,
Center for Tobacco Products, Food and
Drug Administration, Document Control
Center, 10903 New Hampshire Ave.,
Bldg. 71, Rm. G335, Silver Spring, MD
20993–0002, 1–877–287–1373 (choose
Option 5), email: TPSAC@fda.hhs.gov.
Information about becoming a
member on an FDA advisory committee
can also be obtained by visiting FDA’s
website at: https://www.fda.gov/
AdvisoryCommittees/default.htm.
SUPPLEMENTARY INFORMATION: FDA is
requesting nomination for voting
members on the Tobacco Products
Scientific Advisory Committee.
I. General Description of the Committee
Duties
The Tobacco Products Scientific
Advisory Committee advises the
Commissioner of Food and Drugs (the
Commissioner) or designee in
discharging responsibilities related to
the regulation of tobacco products. The
committee reviews and evaluates safety,
dependence, or health issues relating to
tobacco products and provides
appropriate advice, information, and
recommendations to the Commissioner.
II. Criteria for Voting Members
The committee consists of 12
members including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
individuals knowledgeable in the fields
of medicine, medical ethics, science, or
technology involving the manufacture,
evaluation, or use of tobacco products.
Almost all non-Federal members of this
committee serve as Special Government
Employees. The committee includes
nine technically qualified voting
members, selected by the Commissioner
or designee. The nine voting members
include seven members who are
physicians, dentists, scientists, or
healthcare professionals practicing in
the areas of oncology, pulmonology,
cardiology, toxicology, pharmacology,
addiction, or any other relevant
specialty. The nine voting members also
include one member who is an officer
or employee of a State or local
government or of the Federal
Government, and one member who is a
representative of the general public.
Members will be invited to serve for
terms of up to 4 years.
III. Nomination Procedures
Any interested person may nominate
one or more qualified individuals for
membership on the advisory committee.
Self-nominations are also accepted.
VerDate Sep<11>2014
17:26 Oct 16, 2019
Jkt 250001
Nominations must include a current,
complete re´sume´ or curriculum vitae for
each nominee, including current
business address and/or home address,
telephone number, and email address if
available. Nominations must also
specify the advisory committee for
which the nominee is recommended.
Nominations must also acknowledge
that the nominee is aware of the
nomination unless self-nominated. FDA
will ask potential candidates to provide
detailed information concerning such
matters related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflicts of interest.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: October 10, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–22685 Filed 10–16–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–3263]
Request for Nominations of a
Nonvoting Representative of the
Interest of the Tobacco Manufacturing
Industry on the Tobacco Products
Scientific Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
requesting nominations for a nonvoting
representative of the interests of the
tobacco manufacturing industry to serve
on the Tobacco Products Scientific
Advisory Committee (TPSAC), in the
Center for Tobacco Products. FDA seeks
to include the views of women and
men, members of all racial and ethnic
groups, and individuals with and
without disabilities on its advisory
committees and, therefore encourages
nominations of appropriately qualified
candidates from these groups. A
nominee may either be self-nominated
or nominated by an organization.
In addition, FDA is requesting that
any industry organizations interested in
participating in the selection of a
nonvoting representative of the interests
of the tobacco manufacturing industry
to serve on the TPSAC notify FDA in
writing. Nominations will be accepted
SUMMARY:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
55575
for either the representative to serve on
TPSAC or for the selection group
effective with this notice.
DATES: Nomination materials for
prospective candidates should be sent to
FDA by November 18, 2019.
Concurrently, any industry organization
interested in participating in the
selection of an appropriate nonvoting
member to represent the interests of the
tobacco manufacturing industry must
send a letter stating that interest to FDA
by November 18, 2019, (see sections I
and II of this document for further
details).
All nominations for
nonvoting representatives of the
interests of the tobacco manufacturing
industry may be submitted
electronically by accessing the FDA
Advisory Committee Membership
Nomination Portal at: https://
www.accessdata.fda.gov/scripts/
FACTRSPortal/FACTRS/index.cfm, or
by mail to Advisory Committee
Oversight and Management Staff, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 5103,
Silver Spring, MD 20993–0002.
All statements of interest from
industry organizations interested in
participating in the selection process of
nonvoting representatives of the
interests of the tobacco manufacturing
industry nomination should be sent to
Janice O’Connor (see FOR FURTHER
INFORMATION CONTACT).
FOR FURTHER INFORMATION CONTACT:
Janice O’Connor, Office of Science,
Center for Tobacco Products, Food and
Drug Administration, Document Control
Center, 10903 New Hampshire Ave.,
Bldg. 71, Rm. G335, Silver Spring, MD
20993–0002, 1–877–287–1373 (choose
Option 5), email: TPSAC@fda.hhs.gov.
Information about becoming a
member of an FDA advisory committee
can also be obtained by visiting FDA’s
website at: https://www.fda.gov/
AdvisoryCommittees/default.htm.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations for a nonvoting
representative of the interests of the
tobacco manufacturing industry on the
Tobacco Products Scientific Advisory
Committee (TPSAC).
ADDRESSES:
I. General Description of the Committee
Duties
The TPSAC advises the Commissioner
of Food and Drugs (the Commissioner)
or designee in discharging
responsibilities related to the regulation
of tobacco products. The TPSAC
reviews and evaluates safety,
dependence, or health issues relating to
tobacco products and provides
E:\FR\FM\17OCN1.SGM
17OCN1
Agencies
[Federal Register Volume 84, Number 201 (Thursday, October 17, 2019)]
[Notices]
[Pages 55574-55575]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-22685]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-3263]
Request for Nominations for Voting Members on the Tobacco
Products Scientific Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
nominations for members to serve on the Tobacco Products Scientific
Advisory Committee, in the Center for Tobacco Products. FDA seeks to
include the views of women and men, members of all racial and ethnic
groups, and individuals with and without disabilities on its advisory
committees and, therefore, encourages nominations of appropriately
qualified candidates from these groups.
DATES: Nominations received on or before December 16, 2019 will be
given first consideration for membership on the Tobacco Products
Scientific Advisory Committee. Nominations received after December 16,
2019 will be considered for nomination to the committee as later
vacancies occur.
ADDRESSES: All nominations for membership should be sent electronically
by logging into the FDA Advisory Nomination Portal: https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm, or by
mail to Advisory Committee Oversight and Management Staff, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103,
Silver Spring, MD 20993-0002.
[[Page 55575]]
FOR FURTHER INFORMATION CONTACT: Regarding all nomination questions for
membership, the primary contact is: Janice O'Connor, Office of Science,
Center for Tobacco Products, Food and Drug Administration, Document
Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G335, Silver
Spring, MD 20993-0002, 1-877-287-1373 (choose Option 5), email:
[email protected].
Information about becoming a member on an FDA advisory committee
can also be obtained by visiting FDA's website at: https://www.fda.gov/AdvisoryCommittees/default.htm.
SUPPLEMENTARY INFORMATION: FDA is requesting nomination for voting
members on the Tobacco Products Scientific Advisory Committee.
I. General Description of the Committee Duties
The Tobacco Products Scientific Advisory Committee advises the
Commissioner of Food and Drugs (the Commissioner) or designee in
discharging responsibilities related to the regulation of tobacco
products. The committee reviews and evaluates safety, dependence, or
health issues relating to tobacco products and provides appropriate
advice, information, and recommendations to the Commissioner.
II. Criteria for Voting Members
The committee consists of 12 members including the Chair. Members
and the Chair are selected by the Commissioner or designee from among
individuals knowledgeable in the fields of medicine, medical ethics,
science, or technology involving the manufacture, evaluation, or use of
tobacco products. Almost all non-Federal members of this committee
serve as Special Government Employees. The committee includes nine
technically qualified voting members, selected by the Commissioner or
designee. The nine voting members include seven members who are
physicians, dentists, scientists, or healthcare professionals
practicing in the areas of oncology, pulmonology, cardiology,
toxicology, pharmacology, addiction, or any other relevant specialty.
The nine voting members also include one member who is an officer or
employee of a State or local government or of the Federal Government,
and one member who is a representative of the general public. Members
will be invited to serve for terms of up to 4 years.
III. Nomination Procedures
Any interested person may nominate one or more qualified
individuals for membership on the advisory committee. Self-nominations
are also accepted. Nominations must include a current, complete
r[eacute]sum[eacute] or curriculum vitae for each nominee, including
current business address and/or home address, telephone number, and
email address if available. Nominations must also specify the advisory
committee for which the nominee is recommended. Nominations must also
acknowledge that the nominee is aware of the nomination unless self-
nominated. FDA will ask potential candidates to provide detailed
information concerning such matters related to financial holdings,
employment, and research grants and/or contracts to permit evaluation
of possible sources of conflicts of interest.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: October 10, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-22685 Filed 10-16-19; 8:45 am]
BILLING CODE 4164-01-P